

Receipt date: 04/27/2009

APR 27 2009

09756125 - GAU: 1644

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Date Submitted: 4/27/2009

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/756,125
Filing Date	1/9/2001
First Named Inventor	Tadamitsu KISHIMOTO
Art Unit	1644
Examiner Name	Gerald R. EWOLDT
Attorney Docket Number	053466-0296

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	C1	2002/0187150 A1	12/12/2002	Mihara et al.	
	C2	2003/0236260 A1	12/25/2003	Shimojo et al.	
	C3	2004/0115197 A1	06/17/2004	Yoshizaki et al.	
	C4	2006/0292147 A1	12/28/2006	Yoshizaki et al.	
	C5	5,670,373 A	09/23/1997	Kishimoto	
	C6	6,723,319 B1	04/20/2004	Ito et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	C7	CA 2,031,455 A1	06/05/1992	Biotest Pharma GmbH et al.		
	C8	JP 04-187645 A	07/06/1992	Kishimoto et al.		A
	C9	EP 0 381 168 A	08/08/1990	Mochida Pharmaceutical Co., Ltd.		
	C10	EP 0 628 639	12/14/1994	Chugai Seiyaku Kabushiki Kaisha		
	C11	EP 0 791 359 A1	08/27/1997	Chugai Seiyaku Kabushiki Kaisha		
	C12	WO 2004/096273 A1	11/11/2004	Chugai Seiyaku Kabushiki Kaisha		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C13	Office Action in corresponding Chilean Application 1237-2004, 7 pages.	
	C14	Office Action in corresponding Chilean Application 1243-2004, 7 pages.	
	C15	HIRANO et al., "Biological and clinical aspects of interleukin 6," Immunology Today, 1990, 11(12):443-449.	
	C16	SIPE et al., "Cytokine reduction in the treatment of joint conditions," Mediators of Inflammation, 1994, 3:243-256.	

Lined through docs in improper format and not in English.

Examiner
Signature

/Gerald Ewoldt/

Date
Considered

08/08/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WASH_5720734.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 053466/0296	SERIAL NO. 09756125
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Tadamitsu KISHIMOTO, et al.	
		FILING DATE January 9, 2001	GROUP ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
R	A1	5,591,827	1/7/97	Brakenhoff et al.	530	351	
I	A2	5,559,012	9/24/96	Brailly et al.	435	70.21	
I	A3	5,210,075	5/1993	Scholz et al.	514	14	
	A4	5,888,510	03/1999	Kishimoto et al.	424	141.1	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
R	A5	3-291236	04/1990	Japan				
I	A6	4-89433	07/1990	Japan				
I	A7	0 617 126	09/1994	Europe				
I	A8	0 399 429	11/1990	Europe				
I	A9	2 694 767	02/1994	France				
I	A10	92/19759	11/1992	WIPO				
I	A11	39 39 706	03/1991	Federal Republic of Germany				
I	A12	0 572 118	12/1993	Europe				
I	A13	0 409 607	01/1991	Europe				
I	A14	91/07986	06/1991	WIPO				

AOTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

R	A15	Harigai et al., "Rheumatoid Adherent Synovial Cells Produced B Cell Differentiation Factor Activity Neutralizable By Antibody to B Cell Stimulatory Factor-2/Interleukin 6, <i>The Journal of Rheumatology</i> , pp. 1616-1622, (1988)
I	A16	Yasukawa et al., "A Research on Inhibitor of Interleukin-6", <i>Journal of TOSOH Research</i> , Vol. 35(2): pp. 77-91, (1991)
I	A17	Matsuda et al., "Establishment of An Interleukin 6 (IL-6)/B Cell Stimulatory Factor 2-dependent Cell Line And Preparation of Anti-IL 6 Monoclonal Antibodies", <i>Eur. J. Immunol.</i> , Vol. 18, pp. 951-956, (1988) VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1988
I	A18	Hirata et al., "Characterization of IL-6 Receptor Expression by Monoclonal and Polycholan Antibodies", <i>The Journal of Immunology</i> , Vol. 143, pp. 2900-2906, (1989)
I	A19	Hirano et al., "Excessive Production of Interleukin 6/B Cell Stimulatory Factor-2 in rheumatoid Arthritis", <i>Eur. J. Immunol.</i> 18, pp. 1797-1801, (1988). VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1988


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0296		SERIAL NO. 09/756125	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Tadamitsu KISHIMOTO, et al.			
				FILING DATE January 9, 2001		GROUP ART UNIT 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
RV	A20	Yasukawa et al., "A Research on Inhibitor of Interleukin-6", <i>Journal of TOSOH Research</i> , Vol. 35(2): pp. 77-91, (1991)					
	A21	Matsuda et al., "Establishment of An Interleukin 6 (IL-6)/B Cell Stimulatory Factor 2 dependent Cell Line And Preparation of Anti-IL-6 Monoclonal Antibodies", <i>Imm. J. Immunol.</i>, Vol. 18, pp. 951-956, (1988).					
RV	A22	Houssiau, et al., "Interleukin-6 in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis and Other Inflammatory Arthritis", <i>Arthritis and Rheumatism</i> 31, pp. 784-788, (1988)					
	A23	Waage et al., Interleukin-6 Synovial Fluid from Patients with Arthritis", <i>Clinical Immunology and Immunopathology</i> 50, pp. 394-398, (1989), 1989 Academic Press, Inc.					
	A24	Bhardwaj et al., "IL-6/IFN- β In Synovial Effusions of Patients with Rheumatoid Arthritis and Other Arthritides", <i>J. of Immunology</i> 143, pp. 2153-2159, (1989), 1989 The American Association of Immunologists					
	A25	Aderka et al., "IL-6 Inhibits Lipopolysaccharide-induced Tumor Necrosis Factor Production in Cultured Human Monocytes U937 Cells, and In Mice", <i>J of Immunology</i> 143, pp. 3517-3523, (1989), 1989 The American Association of Immunologists					
	A26	Schindler et al., "Correlations and Interactions in the Production of Interleukin-6 (IL-6), IL-1, and Tumor Necrosis Factor (TNF) in Human Blood Mononuclear Cells: IL-6 suppresses IL-1 and TNF", <i>Blood</i> 75, pp. 40-47, (1990), 1990 The American Society of Hematology					
	A27	Saito et al., "Preparation of Soluble Murine IL-6 Receptor and Anti-Murine IL-6 Receptor Antibodies", <i>The Journal of Immunology</i> 147, pp. 168-173, (1991), 1991 The American Association of Immunologists					
	A28	Yasukawa et al., "Inhibitors of Interleukin-6", <i>Toso Kenkyu Hokoku</i> 32(20), pp. 77-91, ABSTRACT, (1991)					
EXAMINER				DATE CONSIDERED			
[Signature]				3/16/01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw li through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0296		SERIAL NO. 09 756125	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Tadamitsu KISHIMOTO, et al.		FILING DATE January 9, 2001	
				GROUP ART UNIT 1644			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A29	Mihara et al., "Interleukin 6 Inhibits Delayed-Type Hypersensitivity and the Development of Adjuvant Arthritis", <u>Eur. J. Immunol.</u> 21, pp. 2327-2331, (1991)					
	A30	Heremans et al., "Protective Effect Of Anti-Interleukin-6 Antibody Against Endotoxin, Associated with Paradoxic Increased IL-6 Levels", <u>Eur. J. Immunol.</u> 22, pp. 2395-2401, (1992), VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1992					
	A31	Wendling et al., "Treatment of Severe Rheumatoid Arthritis by Anti-Interleukin 6 Monoclonal Antibody", <u>J. of Rheumatology</u> 20, pp. 259-262, (1993)					
	A32	Sack et al., "Interleukin-6 In Synovial Fluid is Closely Associated with Chronic Synovitis in Rheumatoid Arthritis" <u>Rheumatol. Int.</u> 13, pp. 45-51, (1993)					
	A33	Madhok et al., "Serum Interleukin-6 Levels in Rheumatoid Arthritis: Correlations with Clinical and Laboratory Indices of Disease Activity", <u>Annals of the Rheumatic Diseases</u> 52, pp. 232-234, (1993)					
	A34	Tilg et al., Interleukin-6 (IL-6) as an Anti-inflammatory Cytokine: Induction of Circulating IL-1 Receptor Antagon and Soluble Tumor Necrosis Factor Receptor p55", <u>Blood</u> 83, pp. 113-118, (1994), 1994 The American Society of Hematology					
	A35	Punzi et al., "Interrelationship Between Synovial Fluid Interleukin (IL)-6, IL-1 β and Disease Activity Indices in Rheumatoid Arthritis", <u>Rheumatol. Int.</u> 14, pp. 83-84, (1994), Springer-Verlag 1994					
	A36	Monier et al., "Growth Factor Activity of IL-6 in the Synovial fluid of Patients with Rheumatoid Arthritis", <u>Clinical and Experimental Rheumatology</u> 12, pp. 595-602, (1994)					
	A37	Fukamachi et al., "Interleukin-6 Receptor (IL-6R) Dynamics in Patients with Rheumatoid Arthritis", <u>Japanese Journal of Inflammation</u> 14, pp. 489-497, (1994)					
EXAMINER 				DATE CONSIDERED 3/16/01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw 1 through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0296		SERIAL NO. 09 756125	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Tadamitsu KISHIMOTO, et al.			
				FILING DATE January 9, 2001		GROUP ART UNIT 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
RV	A38	Tanabe, M. et al., "Remarkable Elevation of Interleukin 6 and Interleukin 8 Levels in the Bone Marrow Serum of Patients with Rheumatoid Arthritis", <i>The Journal of Rheumatology</i> 21, pp. 830-835, (1994)					
	A39	Mihara et al., "Interleukin-6 (IL-6) Induces the Proliferation of Synovial Fibroblastic Cells in the Presence of Soluble IL-6 Receptor", <i>British Journal of Rheumatology</i> 34, pp. 321-325, (1995)					
	A40	Cicutini et al., "Serum IL-4, IL-10 and IL-6 Levels in Inflammatory Arthritis", <i>Rheumatol. Int.</i> 14, pp. 201-206, (1995), Springer-Verlag 1995					
	A41	Scholz et al., "Interleukin 6 in diseases: Cause or Cure?", <i>Immunopharmacology</i> 31, pp. 131-150, (1996), 1996 Elsevier Science B.V.					
	A42	Santo et al., "Differential Effects of IL-6 on Systemic and Central Production of TNF: A Study with IL-6-Deficient Mice", <i>Cytokine</i> 9, pp. 300-306, (1997), 1997 Academic Press Limited					
	A43	Suzuki et al., "Anti-human Interleukin-6 Receptor Antibody Inhibits Myeloma Growth in vivo", <i>Eur. J. Immunol.</i> 22, pp. 1989-1993, (1992), VCH Verlagsgesellschaft mbH, D-6940 Weinheim 1992					
	A44	Suzuki et al., "Anti-Murine IL-6 Receptor Antibody Inhibits IL-6 Effects in Vivo", <i>Immunology Letters</i> 30, pp. 17-21, (1991), 1991 Elsevier Science Publishers B.V.					
	A45	Sato et al., "Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth", <i>Cancer Research</i> 53, pp. 851-856, (1993)					
	A46	Wijdenes et al., "Interleukin-6 Antibodies in Rheumatoid Arthritis", <i>Journal of Interferon Research</i> 14, pp. 297-298, (1994)					
	A47	Herve, P. et al., <i>Immunological Reviews</i> 129, pp. 31-55, (1992)					
EXAMINER 				DATE CONSIDERED 3/16/01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							